Improving immunogenicity and effectiveness of influenza vaccine in older adults

Expert Review of Vaccines

Volumn 10, Issue 11, 2011, Pages 1529-1537

  Cao, Weiping ^a   Kim, Jin Hyang ^a   Chirkova, Tatiana ^a   Reber, Adrian J ^a   Biber, Renata ^a   Shay, David K ^a   Sambhara, Suryaprakash ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

aging; immunosenescence; influenza; vaccination

Indexed keywords

AS 03; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MIFAMURTIDE; PLACEBO; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

2009 H1N1 INFLUENZA; ADAPTIVE IMMUNITY; B LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSENESCENCE; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INJECTION SITE REACTION; INNATE IMMUNITY; MORTALITY; NATURAL KILLER CELL; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SEASONAL INFLUENZA; SENESCENCE; T LYMPHOCYTE; VIRUS STRAIN;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; AGING; DRUG DISCOVERY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNITY, INNATE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 80455126055     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.137     Document Type: Review

References (83)

1. Walford RL. The immunologic theory of aging. Munksgaard Press, Copenhagen, Denmark (1969).
2. Grolleau-Julius A, Ray D, Yung RL. The role of epigenetics in aging and autoimmunity. Clin. Rev. Allergy Immunol. 39(1), 42-50 (2010).
3. Ksiazek K. Oxidative stress as an universal cause of aging - from human somatic cells to the unicellular yeast and bacteria. Postepy. Biochem. 56(3), 260-268 (2010).
4. Romano AD, Serviddio G, de Matthaeis A, Bellanti F, Vendemiale G. Oxidative stress and aging. J. Nephrol. 23(Suppl. 15), S29-S36 (2010).
5. Sansoni P, Cossarizza A, Brianti V et al. Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 82(9), 2267-2273 (1993).
6. Vitale M, Zamai L, Neri LM et al. The impairment of natural killer function in the healthy aged is due to a postbinding deficient mechanism. Cell Immunol. 145(1), 1-10 (1992).
7. Ogata K, Yokose N, Tamura H et al. Natural killer cells in the late decades of human life. Clin. Immunol. Immunopathol. 84(3), 269-275 (1997). (Pubitemid 27398026)
8. Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol. 20, 825-852 (2002). (Pubitemid 34293441)
9. Zissel G, Schlaak M, Muller-Quernheim J. Age-related decrease in accessory cell function of human alveolar macrophages. J. Investig. Med. 47(1), 51-56 (1999). (Pubitemid 129537257)
10. Kohut ML, Senchina DS, Madden KS, Martin AE, Felten DL, Moynihan JA. Age effects on macrophage function vary by tissue site, nature of stimulant, and exercise behavior. Exp. Gerontol. 39(9), 1347-1360 (2004). (Pubitemid 39360376)
11. Della Bella S, Bierti L, Presicce P et al. Peripheral blood dendritic cells and monocytes are differently regulated in the elderly. Clin. Immunol. 122(2), 220-228 (2007). (Pubitemid 46073895)
12. Jing Y, Shaheen E, Drake RR, Chen N, Gravenstein S, Deng T. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum. Immunol. 70(10), 777-784 (2009).
13. Agrawal A, Agrawal S, Cao JN, Su H, Osann K, Gupta S. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J. Immunol. 178(11), 6912-6922 (2007). (Pubitemid 46847417)
14. Plowden J, Renshaw-Hoelscher M, Engleman C, Katz J, Sambhara S. Innate immunity in aging: impact on macrophage function. Aging Cell 3(4), 161-167 (2004). (Pubitemid 40246681)
15. Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impired Toll-like receptor expression and function in aging. J. Immunol. 169(9), 4697-4701 (2002). (Pubitemid 35217128)
16. Sambhara S, Kurichh A, Miranda R et al. Severe impairment of primary but not memory responses to influenza viral antigens in aged mice: costimulation in vivo partially reverses impaired primary immune responses. Cell Immunol. 210(1), 1-4 (2001). (Pubitemid 32756935)
17. Sambhara S, Kurichh A, Miranda R et al. Enhanced immune responses and resistance against infection in aged mice conferred by Flu-ISCOMs vaccine correlate with up-regulation of costimulatory molecule CD86. Vaccine 16(18), 1698-1704 (1998). (Pubitemid 28545098)
18. Linton PJ, Li SP, Zhang Y, Bautista B, Huynh Q, Trinh T. Intrinsic versus environmental influences on T-cell responses in aging. Immunol. Rev. 205, 207-219 (2005). (Pubitemid 40780187)
19. Shaw AC, Panda A, Joshi SR, Qian F, Allore HG, Montgomery RR. Dysregulation of human Toll-like receptor function in aging. Ageing Res. Rev. 10(3), 346-353 (2011).
20. Panda A, Qian F, Mohanty S et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J. Immunol. 184(5), 2518-2527 (2010).
21. Van Duin D, Allore HG, Mohanty S et al. Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J. Infect. Dis. 195(11), 1590-1597 (2007). (Pubitemid 46799216)
22. Van Duin D, Mohanty S, Thomas V et al. Age-associated defect in human TLR-1/2 function. J. Immunol. 178(2), 970-975 (2007). (Pubitemid 46095170)
23. Aspinall R, Andrew D. Thymic involution in aging. J. Clin. Immunol. 20(4), 250-256 (2000). (Pubitemid 30619396)
24. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat. Immunol. 5(2), 133-139 (2004). (Pubitemid 38208354)
25. Flores KG, Li J, Sempowski GD, Haynes BF, Hale LP. Analysis of the human thymic perivascular space during aging. J. Clin. Invest. 104(8), 1031-1039 (1999). (Pubitemid 29536313)
26. + T-regulatory cells. J. Immunother. 29(3), 313-319 (2006). (Pubitemid 44297299)
27. Aggarwal S, Gupta S. Increased activity of caspase 3 and caspase 8 in anti-Fas-induced apoptosis in lymphocytes from ageing humans. Clin. Exp. Immunol. 117(2), 285-290 (1999). (Pubitemid 29343599)
28. Aggarwal S, Gupta S. Increased apoptosis of T cell subsets in aging humans: altered expression of Fas (CD95), Fas ligand, Bcl-2, and Bax. J. Immunol. 160(4), 1627-1637 (1998). (Pubitemid 28106447)
29. + lymphocytes in the aged microenvironment results in a memoryenriched population. J. Immunol. 162(2), 711-717 (1999). (Pubitemid 29035391)
30. + T cell clonal expansion in aging is due to defects in antigen presenting cell function. Cell Immunol. 229(2), 86-92 (2004). (Pubitemid 39330216)
31. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J. Virol. 75(24), 12182-12187 (2001). (Pubitemid 33115891)
32. Naylor L, Li G, Vallejo AN et al. The influence of age on T cell generation and TCR diversity. J. Immunol. 174(11), 7446-7452 (2005). (Pubitemid 40705717)
33. Yager EJ, Ahmed M, Lanzer K, Randall TD, Woodland DL, Blackman MA. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J. Exp. Med. 205(3), 711-723 (2008). (Pubitemid 351439315)
34. + regulatory T cells in aged Balb/c mice. J. Leukoc. Biol. 81(6), 1386-1394 (2007). (Pubitemid 46827961)
35. Rosenkranz D, Weyer S, Tolosa E et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J. Neuroimmunol. 188(1-2), 117-127 (2007). (Pubitemid 47095016)
36. + CD25high regulatory T cells increases with age. Clin. Exp. Immunol. 140(3), 540-546 (2005). (Pubitemid 40813966)
37. Buffa S, Bulati M, pellicano M et al. B cell immunosenescence: different features of naive and memory B cells in elderly. Biogerontology DOI: 10.1007/s10522-011- 9353-4 (2011) (Epub ahead of print).
38. Gibson KL, Wu YC, Barnett Y et al. B-celldiversity decreases in old age and is correlated with poor health status. Aging Cell 8(1), 18-25 (2009).
39. Han S, Yang K, Ozen Z et al. Enhanced differentiation of splenic plasma cells but diminished long-lived high-affinity bone marrow plasma cells in aged mice. J. Immunol. 170(3), 1267-1273 (2003). (Pubitemid 36139492)
40. Cunha BA. Influenza: historical aspects of epidemics and pandemics. Infect. Dis. Clin. North Am. 18(1), 141-155 (2004). (Pubitemid 38479489)
41. Hampson AW, Mackenzie JS. The influenza viruses. Med. J. Aust. 185(10 Suppl.), S39-S43 (2006). (Pubitemid 44823405)
42. Virelizier JL, Postlethwaite R, Schild GC, Allison AC. Antibody responses to antigenic determinants of influenza virus hemagglutinin. I. Thymus dependence of antibody formation and thymus independence of immunological memory. J. Exp. Med. 140(6), 1559-1570 (1974).
43. Ennis FA, Rook AH, Qi YH et al. HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet 2(8252), 887-891 (1981). (Pubitemid 11008426)
44. Jenne DE, Tschopp J. Granzymes, a family of serine proteases released from granules of cytolytic T lymphocytes upon T cell receptor stimulation. Immunol. Rev. 103, 53-71 (1988).
45. Pasternack MS, Eisen HN. A novel serine esterase expressed by cytotoxic T lymphocytes. Nature 314(6013), 473-475 (1985).
46. Hosaka Y, Sasao F, Yamanaka K, Bennink JR, Yewdell JW. Recognition of noninfectious influenza virus by class I-restricted murine cytotoxic T lymphocytes. J. Immunol. 140(2), 606-610 (1988).
47. Francis T Jr. Vaccination against influenza. Bull. World Health Organ. 8(5-6), 725-741 (1953).
48. Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr. Top. Microbiol. Immunol. 333, 43-82 (2009).
49. Fiore AE, Uyeki TM, Broder K et al. Prevention and control of influenza withvaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59(RR-8), 1-62 (2010).
50. Gorse GJ, O'Connor TZ, Young SL et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 21(17-18), 2133-2144 (2003).
51. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the communitydwelling elderly. N. Engl. J. Med. 357(14), 1373-1381 (2007). (Pubitemid 47535592)
52. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N. Engl. J. Med. 348(14), 1322-1332 (2003). (Pubitemid 36384099)
53. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect. Dis. 7(10), 658-666 (2007). (Pubitemid 47444564)
54. Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, Jackson LA. Influenza vaccination and risk of communityacquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 372(9636), 398-405 (2008).
55. Rupprecht CE, Briggs D, Brown CM et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm. Rep. 59(RR-2), 1-9 (2010).
56. Fischer M, Lindsey N, Staples JE et al. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 59(RR-1), 1-27 (2010).
57. Gross PA. Review: inactivated vaccines provide the greatest protection against influenza in healthy persons. ACP J. Club 136(3), 103 (2002).
58. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24(8), 1159-1169 (2006). (Pubitemid 43202262)
59. O'Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin. Pharmacol. Ther. 82(6), 740-744 (2007). (Pubitemid 350114825)
60. Parodi V, de Florentiis D, Martini M, Ansaldi F. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging 28(2), 93-106 (2011).
61. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 26(26), 3209-3222 (2008).
62. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19(17-19), 2673-2680 (2001). (Pubitemid 32234288)
63. O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines 10(4), 447-462 (2011).
64. De Donato S, Granoff D, Minutello M, Lecchi G et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17(23-24), 3094-3101 (1999). (Pubitemid 29366990)
65. Minutello M, Senatore F, Cecchinelli G et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17(2), 99-104 (1999). (Pubitemid 28494106)
66. Gasparini R, Pozzi T, Montomoli E et al. Increased immunogenicity of the MF59- adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol. 17(2), 135-140 (2001). (Pubitemid 32900039)
67. Balli G, Hancock K, Hoschler K et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA 106(19), 7962-7967 (2009).
68. Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin. Vaccine Immunol. 17(11), 1817-1817 (2010).
69. + T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877-3882 (2009).
70. Wack A, Baudner BC, Hilbert AK et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26(4), 552-561 (2008).
71. Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 14(6), 478-484 (1996).
72. Baras B, Bouveret N, Devaster JM et al. A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respir. Viruses 2(6), 251-260 (2008).
73. Leroux-Roels, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomized controlled trial. Lancet 370(9587), 580-589 (2007). (Pubitemid 47247854)
74. Moris P, van der Most R, Leroux-Roels I et al. H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J. Clin. Immunol. 31(3), 443-454 (2011).
75. Leroux-Roels, Roman F, Forqus S et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomized primary study. Vaccine 28(3), 849-857 (2010).
76. Heijimans S, De Meulemeester M, Reynders P et al. Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J. Infect. Dis. 203(8), 1054-1062 (2011).
77. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin. Infect. Dis. 51(6), 668-677 (2010).
78. Couch RB, Winokur P, Brady R et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25(44), 7656-7663 (2007). (Pubitemid 47554468)
79. Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med. 166(10), 1121-1127 (2006). (Pubitemid 43765184)
80. Palache AM, Beyer WE, Sprenger MJ et al. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 11(1), 3-9 (1993). (Pubitemid 23080723)
81. Chen WH, Cross AS, Edelman R et al. Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine 29(16), 2865-2873 (2011).
82. Sullivan SJ, Jacobson R, Poland GA. Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Rev. Vaccines 9(10), 1127-1133 (2010).
83. CDC. Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States. MMWR Morb. Mortal. Wkly Rep. 59(16), 485-486 (2010).